nach oben

Current Hepatology Reports

Erschienen in:

19.09.2018 | Fatty Liver Disease (Z Younossi, Section Editor)

The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis

verfasst von: Ralf Weiskirchen, Frank Tacke

Erschienen in: Current Hepatology Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The dramatic increase in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) fostered the development and evaluation of non-invasive, imaging based methods for diagnosing NAFLD, NASH, and its complications. We herein review different radiologic modalities in diagnosing steatosis, fibrosis, and liver cirrhosis.

Recent Findings

While routine abdominal ultrasound with hyperechogenic liver structure only detects moderate to severe steatosis, controlled attenuation parameter (CAP), magnetic resonance spectroscopy (MRS), and, especially, MRI-proton density fat fraction (MRI-PDFF) are more sensitive to diagnose and quantify steatosis. MRI-PDFF appears suitable to monitor treatment-related changes in liver fat in clinical trials. Liver fibrosis is related to hepatic and extrahepatic morbidity and mortality in NAFLD. Fibrosis and cirrhosis can be suspected by ultrasound-based elastography techniques (vibration-controlled transient elastography, VCTE; acoustic resonance forced impulse imaging, ARFI; shear wave elastography, SWE), which may be used to screen for fibrosis in high-risk patients. MR elastography (MRE) appears advantageous to quantify and stage fibrosis, while angiographic hepatic venous pressure gradient (HVPG) measurement can confirm portal hypertension in cirrhosis. Screening for hepatocellular carcinoma (HCC) in cirrhotic livers is done by ultrasound; suspicious nodules are followed by multiphasic CT/MRI, contrast-enhanced ultrasound (CEUS), or contrast-enhanced MRI.

Summary

Different radiologic modalities exist to screen, diagnose, stage, and monitor steatosis, steatohepatitis, fibrosis, and HCC, thereby complementing liver biopsy and blood biomarkers in the management of patients with NAFLD.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.CrossRefPubMed

Parikh ND, Marrero WJ, Wang J, Steuer J, Tapper EB, Konerman M, et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology. 2017 Aug 17. https://doi.org/10.1002/hep.29473.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Geier A, Kondili LA, Lazarus JV, Loomba R, Manns MP, Marchesini G, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896–904. https://doi.org/10.1016/j.jhep.2018.05.036

• Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. https://doi.org/10.1002/hep.29085 This meta-analysis established the link between fibrosis and mortality in NAFLD. CrossRefPubMedPubMedCentral

•• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004 This is the first international, multidisciplinary guideline on the management of NAFLD. CrossRef

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.CrossRefPubMed

• Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology. 2018;68(1):349–60. https://doi.org/10.1002/hep.29721. https://doi.org/10.1002/hep.29721. An important and recent review article on diagnostic modalities in NAFLD.

Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008;28(5):705–12. https://doi.org/10.1111/j.1478-3231.2008.01691.x.CrossRefPubMed

Loomba R. Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol. 2018;68(2):296–304. https://doi.org/10.1016/j.jhep.2017.11.028.CrossRefPubMed

10.

Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F, et al. Fibrosis imaging: current concepts and future directions. Adv Drug Deliv Rev. 2017;121:9–26. https://doi.org/10.1016/j.addr.2017.10.013.CrossRefPubMedPubMedCentral

11.

Azhari H. Ultrasound: medical imaging and beyond (an invited review). Curr Pharm Biotechnol. 2012;13(11):2104–16. https://doi.org/10.2174/138920112802502033.CrossRefPubMed

12.

Seo J, Kim Y-S. Ultrasound imaging and beyond: recent advances in medical ultrasound. Biom Eng Lett. 2017;7:57–8. https://doi.org/10.1007/s13534-017-0030-7.CrossRef

13.

Mozaffari MH, Lee WS. Freehand 3-D ultrasound imaging: a systematic review. Ultrasound Med Biol. 2017;43(10):2099–124. https://doi.org/10.1016/j.ultrasmedbio.2017.06.009.CrossRefPubMed

14.

Miller DL, Smith NB, Bailey MR, Czarnota GJ, Hynynen K, Makin IR. Bioeffects Committee of the American Institute of Ultrasound in Medicine Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med. 2012;31(4):623–34. https://doi.org/10.7863/jum.2012.31.4.623.CrossRefPubMedPubMedCentral

15.

Taylor KJ, Gorelick FS, Rosenfield AT, Riely CA. Ultrasonography of alcoholic liver disease with histological correlation. Radiology. 1981;141(1):157–61. https://doi.org/10.1148/radiology.141.1.6270725.CrossRefPubMed

16.

Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52(4):579–85. https://doi.org/10.1016/j.jhep.2010.01.008.CrossRefPubMed

17.

Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. https://doi.org/10.1053/j.gastro.2010.09.038.CrossRefPubMed

18.

Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102(12):2716–7. https://doi.org/10.1111/j.1572-0241.2007.01520.x.CrossRefPubMed

19.

Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47(2):239–44. https://doi.org/10.1016/j.jhep.2007.02.007.CrossRefPubMed

20.

Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2008;134(1):85–94. https://doi.org/10.1053/j.gastro.2007.10.024.CrossRefPubMed

21.

Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(22):6821–5. https://doi.org/10.3748/wjg.v20.i22.6821.CrossRefPubMedPubMedCentral

22.

Battaglia V, Cervelli R. Liver investigations: updating on US technique and contrast-enhanced ultrasound (CEUS). Eur J Radiol. 2017;96:65–73. https://doi.org/10.1016/j.ejrad.2017.08.029.CrossRefPubMed

23.

Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol. 2007;41(6):624–9. https://doi.org/10.1097/01.mcg.0000225680.45088.01.CrossRefPubMed

24.

Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006–16. https://doi.org/10.1016/j.jhep.2016.06.005.CrossRefPubMedPubMedCentral

25.

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005.CrossRefPubMed

26.

Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13. https://doi.org/10.1016/j.ultrasmedbio.2003.07.001.CrossRefPubMed

27.

Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G852–8. https://doi.org/10.1152/ajpgi.00521.2005.CrossRefPubMed

28.

Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand? World J Gastroenterol. 2016;22(32):7236–51. https://doi.org/10.3748/wjg.v22.i32.7236.CrossRefPubMedPubMedCentral

29.

• Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30. https://doi.org/10.1016/j.jhep.2016.12.022 This individual patient data-based meta-analysis identified important confounders for CAP measurement. CrossRefPubMed

30.

Desai NK, Harney S, Raza R, Al-Ibraheemi A, Shillingford N, Mitchell PD, et al. Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients. J Pediatr. 2016;173:160–164.e1. https://doi.org/10.1016/j.jpeds.2016.03.021.CrossRefPubMedPubMedCentral

31.

de Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026–31. https://doi.org/10.1016/j.jhep.2013.12.018.CrossRefPubMed

32.

Caussy C, Reeder SB, Sirlin CB, Loomba R. Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018 Jan 21;68:763–72. https://doi.org/10.1002/hep.29797.CrossRefPubMedPubMedCentral

33.

Kjærgaard M, Thiele M, Jansen C, Stæhr Madsen B, Görtzen J, Strassburg C, et al. High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. PLoS One. 2017;12(4):e0173992. https://doi.org/10.1371/journal.pone.0173992.CrossRefPubMedPubMedCentral

34.

Plewes DB, Kucharczyk W. Physics of MRI: a primer. J Magn Reson Imaging. 2012;35(5):1038–54. https://doi.org/10.1002/jmri.23642.CrossRefPubMed

35.

Handbook of MRI technique, 4th edition. Ed.: C. Westbrook, John Wiley & Sons, 2014. ISBN: 978–1–118-66162-8.

36.

Kim KH, Do WJ, Park SH. Improving resolution of MR images with an adversarial network incorporating images with different contrast. Med Phys. 2018;45:3120–31. https://doi.org/10.1002/mp.12945.CrossRefPubMed

37.

Ibrahim MA, Dublin AB. Magnetic Resonance Imaging (MRI), Gadolinium. 2018 Jan 25. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK482487/

38.

Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, et al. Adolinium-based contrast agent-related toxicities. CNS Drugs. 2018;32(3):229–40. https://doi.org/10.1007/s40263-018-0500-1.CrossRefPubMed

39.

Rogowska J, Olkowska E, Ratajczyk W, Wolska L. Gadolinium as a new emerging contaminant of aquatic environments. Environ Toxicol Chem. 2018;37(6):1523–34. https://doi.org/10.1002/etc.4116.CrossRefPubMed

40.

Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67(4):1348–59. https://doi.org/10.1002/hep.29639.CrossRefPubMedPubMedCentral

41.

Kim KY, Song JS, Kannengiesser S, Han YM. Hepatic fat quantification using the proton density fat fraction (PDFF): utility of free-drawn-PDFF with a large coverage area. Radiol Med. 2015;120(12):1083–93. https://doi.org/10.1007/s11547-015-0545-x.CrossRefPubMed

42.

Kim M, Kang BK, Jun DW. Comparison of conventional sonographic signs and magnetic resonance imaging proton density fat fraction for assessment of hepatic steatosis. Sci Rep. 2018;8(1):7759. https://doi.org/10.1038/s41598-018-26019-x.CrossRefPubMedPubMedCentral

43.

Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, et al. Characterisation of liver fat in the UK biobank cohort. PLoS One. 2017;12(2):e0172921. https://doi.org/10.1371/journal.pone.0172921.CrossRefPubMedPubMedCentral

44.

• Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology. 2017;153(3):753–61. https://doi.org/10.1053/j.gastro.2017.06.005 This study demonstrated agreement between MRI-PDFF and histological steatosis. CrossRefPubMedPubMedCentral

45.

Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902–10. https://doi.org/10.1111/j.1478-3231.2012.02781.x.CrossRefPubMed

46.

Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. Mol Aspects Med. 2018. https://doi.org/10.1016/j.mam.2018.06.003

47.

Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control. 2002;49(4):436–46. https://doi.org/10.1109/58.996561.CrossRefPubMed

48.

Sandrin L, Tanter M, Catheline S, Fink M. Shear modulus imaging with 2-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control. 2002;49(4):426–35. https://doi.org/10.1109/58.996560.CrossRefPubMed

49.

Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2012;8(9):605–7.

50.

• Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):570–8. https://doi.org/10.1016/j.jhep.2016.04.023 This work compared cross-sectional and longitudinal assessments of several serum biomarker tests and elastography in a large cohort of NAFLD patients. CrossRefPubMed

51.

U.S. Food & Drug Administration (FDA): Echosens’s FibroScan® System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf12/k123806.pdf. last downloaded: September 17, 2018.

52.

Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, et al. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol. 2013;58(5):928–35. https://doi.org/10.1016/j.jhep.2012.12.021.CrossRefPubMed

53.

Jaffer OS, Lung PF, Bosanac D, Patel VM, Ryan SM, Heneghan MA, et al. Acoustic radiation force impulse quantification: repeatability of measurements in selected liver segments and influence of age, body mass index and liver capsule-to-box distance. Br J Radiol. 2012;85(1018):e858–63. https://doi.org/10.1259/bjr/74797353.CrossRefPubMedPubMedCentral

54.

Palmeri ML, Wang MH, Dahl JJ, Frinkley KD, Nightingale KR. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol. 2008;34:546–58. https://doi.org/10.1016/j.ultrasmedbio.2007.10.009.CrossRefPubMedPubMedCentral

55.

Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol. 2011;55(3):666–72. https://doi.org/10.1016/j.jhep.2010.12.019.CrossRefPubMedPubMedCentral

56.

Karlas T, Dietrich A, Peter V, Wittekind C, Lichtinghagen R, Garnov N, et al. Evaluation of transient Elastography, acoustic radiation force impulse imaging (ARFI), and enhanced liver function (ELF) score for detection of fibrosis in morbidly obese patients. PLoS One. 2015;10(11):e0141649. https://doi.org/10.1371/journal.pone.0141649.CrossRefPubMedPubMedCentral

57.

Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol. 2012;81(3):e325–31. https://doi.org/10.1016/j.ejrad.2011.10.029.CrossRefPubMed

58.

Orlacchio A, Bolacchi F, Antonicoli M, Coco I, Costanzo E, Tosti D, et al. Liver elasticity in NASH patients evaluated with real-time elastography (RTE). Ultrasound Med Biol. 2012;38(4):537–44. https://doi.org/10.1016/j.ultrasmedbio.2011.12.023.CrossRefPubMed

59.

Chen Y, Luo Y, Huang W, Hu D, Zheng RQ, Cong SZ, et al. Machine-learning-based classification of real-time tissue elastography for hepatic fibrosis in patients with chronic hepatitis B. Comput Biol Med. 2017;89:18–23. https://doi.org/10.1016/j.compbiomed.2017.07.012.CrossRefPubMed

60.

Bercoff J, Tanter M, Fink M. Supersonic shear imaging: a new technique for soft tissue elasticity mapping. IEEE Trans Ultrason Ferroelectr Freq Control. 2004;51(4):396–409. https://doi.org/10.1109/TUFFC.2004.1295425.CrossRefPubMed

61.

Deng H, Qi X, Zhang T, Qi X, Yoshida EM, Guo X. Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases: a meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(1):91–8. https://doi.org/10.1080/17474124.2018.1412257.CrossRefPubMed

62.

Herrmann E, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018;67(1):260–72. https://doi.org/10.1002/hep.29179.CrossRefPubMed

63.

Mariappan YK, Glaser KJ, Ehman RL. Magnetic resonance elastography: a review. Clin Anat. 2010;23(5):497–511. https://doi.org/10.1002/ca.21006.CrossRefPubMedPubMedCentral

64.

Cui J, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015;41(12):1271–80. https://doi.org/10.1111/apt.13196.CrossRefPubMedPubMedCentral

65.

• Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607.e2. https://doi.org/10.1053/j.gastro.2016.10.026 This work directly compared MRE and VCTE, demonstrating superior performance of MRE for fibrosis staging. CrossRefPubMed

66.

Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, Le MD, Hooker J, Tu X, Bettencourt R, Yin M, Sirlin CB, Ehman RL, Nakajima A, Loomba R. Magnetic resonance vs transient elastography analysis of patients with non-alcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.05.059.

67.

Xanthakos SA, Podberesky DJ, Serai SD, Miles L, King EC, Balistreri WF, et al. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr. 2014;164(1):186–8. https://doi.org/10.1016/j.jpeds.2013.07.050.CrossRefPubMed

68.

Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol. 2018;98:82–9. https://doi.org/10.1016/j.ejrad.2017.11.003.CrossRefPubMed

69.

Pavlides M, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017;37(7):1065–73. doi. https://doi.org/10.1111/liv.13284.CrossRefPubMedPubMedCentral

70.

Farrar CT, Gale EM, Kennan R, Ramsay I, Masia R, Arora G, et al. CM-101: type I collagen-targeted MR imaging probe for detection of liver fibrosis. Radiology. 2018;287(2):581–9. doi. https://doi.org/10.1148/radiol.2017170595.CrossRefPubMed

71.

Ehling J, Bartneck M, Fech V, Butzbach B, Cesati R, Botnar R, et al. Elastin-based molecular MRI of liver fibrosis. Hepatology. 2013;58(4):1517–8. doi. https://doi.org/10.1002/hep.26326.CrossRefPubMed

72.

Cheung JS, Fan SJ, Gao DS, Chow AM, Man K, Wu EX. Diffusion tensor imaging of liver fibrosis in an experimental model. J Magn Reson Imaging. 2010;32(5):1141–8. https://doi.org/10.1002/jmri.22367.CrossRefPubMed

73.

Li X, Liang Q, Zhuang L, Zhang X, Chen T, Li L, et al. Preliminary study of MR diffusion tensor imaging of the liver for the diagnosis of hepatocellular carcinoma. PLoS One. 2015;10(8):e0135568. https://doi.org/10.1371/journal.pone.0135568.CrossRefPubMedPubMedCentral

74.

Wong OL, Leung TWT, Lo GG, Yuan J, Li WW, Noseworthy MD. Intrasession and intersession repeatability of diffusion tensor imaging in healthy human liver. J Comput Assist Tomogr. 2017;41(4):578–85. https://doi.org/10.1097/RCT.0000000000000572.CrossRefPubMed

75.

Ajmera V, Loomba R. Can elastography differentiate isolated fatty liver from nonalcoholic steatohepatitis? Semin Liver Dis. 2018;38(1):14–20. https://doi.org/10.1055/s-0037-1618587.CrossRefPubMed

76.

Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–35. https://doi.org/10.1002/hep.23425 NA.CrossRefPubMed

77.

Lv S, Jiang S, Liu S, Dong Q, Xin Y, Xuan S. Noninvasive quantitative detection methods of liver fat content in nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2018;6(2):217–21. https://doi.org/10.14218/JCTH.2018.00021.CrossRefPubMedPubMedCentral

78.

Praveenraj P, Gomes RM, Basuraju S, Kumar S, Senthilnathan P, Parathasarathi R, et al. Preliminary evaluation of acoustic radiation force impulse shear wave imaging to detect hepatic fibrosis in morbidly obese patients before bariatric surgery. J Laparoendosc Adv Surg Tech A. 2016;26(3):192–5. https://doi.org/10.1089/lap.2015.0396.CrossRefPubMed

79.

Bota S, Sporea I, Sirli R, Popescu A, Danila M, Costachescu D. Intra- and interoperator reproducibility of acoustic radiation force impulse (ARFI) elastography--preliminary results. Ultrasound Med Biol. 2012;38(7):1103–8. https://doi.org/10.1016/j.ultrasmedbio.2012.02.032.CrossRefPubMed

80.

Liu H, Fu J, Hong R, Liu L, Li F. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One. 2015;10(7):e0127782. https://doi.org/10.1371/journal.pone.0127782.CrossRefPubMedPubMedCentral

81.

Shiraishi A, Hiraoka A, Aibiki T, Okudaira T, Kawamura T, Imai Y, et al. Real-time tissue elastography: non-invasive evaluation of liver fibrosis in chronic liver disease due to HCV. Hepato-Gastroenterology. 2014;61(135):2084–90.PubMed

82.

Choong CC, Venkatesh SK, Siew EP. Accuracy of routine clinical ultrasound for staging of liver fibrosis. J Clin Imaging Sci. 2012;2:58. https://doi.org/10.4103/2156-7514.101000.CrossRefPubMedPubMedCentral

83.

Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, et al. Quantitative elastography methods in liver disease: current evidence and future directions. Radiology. 2018;286(3):738–63. https://doi.org/10.1148/radiol.2018170601.CrossRefPubMedPubMedCentral

84.

de Franchis R, Baveno VI, Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52. https://doi.org/10.1016/j.jhep.2015.05.022.CrossRefPubMed

85.

European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60. https://doi.org/10.1016/j.jhep.2018.03.024.CrossRef

86.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.CrossRef

87.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. https://doi.org/10.1016/j.jhep.2018.03.019.CrossRefPubMed

88.

Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. https://doi.org/10.1111/j.1365-2036.2009.04014.x.CrossRefPubMedPubMedCentral

89.

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2 An important recent review on diagnosis and management of liver cancer. CrossRefPubMed

90.

Di Martino M, De Filippis G, De Santis A, Geiger D, Del Monte M, Lombardo CV, et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol. 2013;23(4):887–96. https://doi.org/10.1007/s00330-012-2691-z.CrossRefPubMed

91.

Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut. 2018;67:1674–82. https://doi.org/10.1136/gutjnl-2017-315384.CrossRefPubMed

92.

• Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(3):626–37. https://doi.org/10.1053/j.gastro.2015.11.048 This work directly compared transient elastography- and MRI-based methods for steatosis and fibrosis assessment in biopsy-confirmed NAFLD patients. CrossRefPubMed

93.

Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016;9(5):692–701. https://doi.org/10.1177/1756283X16656735.CrossRefPubMedPubMedCentral

Titel: The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis
verfasst von: Ralf Weiskirchen
Frank Tacke
Publikationsdatum: 19.09.2018
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2018
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0421-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Update on Pediatric Fatty Liver Disease

Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice

Pathogenesis of NASH: the Impact of Multiple Pathways

Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma

Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls